.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Dr. Anna D. Kosinska

Munich/ DE

Technical University of Munich / Helmholtz Munich

Speaker

25/09/2023
Poster
P-1-100
Generation of a pan-genotypic MVA vector for targeting chronic hepatitis B via therapeutic vaccination
Chronic Infections

Further involvements

25/09/2023
Poster
P-1-61
Recombinant mosaic HBV capsid particles foster adaptive immunity against the most prevalent HBV genotypes by therapeutic vaccination
Immune Prevention and Therapy
25/09/2023
Poster
P-1-100
Generation of a pan-genotypic MVA vector for targeting chronic hepatitis B via therapeutic vaccination
Chronic Infections
25/09/2023
Poster
P-1-115
HBV-specific T cell immunity in tissue and circulation: a system level analysis
Chronic Infections